Dual role of ERK5 in the regulation of T cell receptor expression at the T cell surface

Xavier Rovira-Clavé,* Maria Angulo-Ibáñez,* Cathy Tournier,† Manuel Reina,*‡ and Enric Espel†

*Celltec-UB, Department of Cell Biology, and †Department of Physiology and Immunology, Faculty of Biology, Universitat de Barcelona, Barcelona, Barcelona, Spain; and ‡University of Manchester, Faculty of Life Sciences, Manchester, United Kingdom

RECEIVED JANUARY 28, 2015; REVISED JULY 8, 2015; ACCEPTED AUGUST 5, 2015. DOI: 10.1189/jlb.2A0115-034R

ABSTRACT

Regulation of the levels of the TCR/CD3 complex at the cell surface is critical to proper T cell development and mature T cell activation. We provide evidence that the MAPK ERK5 regulates the surface expression of the TCR/CD3 complex by controlling the degradation of the CD3ζ chain and the recovery of the complex after anti-CD3ε stimulation. ERK5 knockdown led to TCR/CD3 up-regulation at the cell surface and increased amounts of the CD3ζ chain. Inhibition of the MEK5-dependent phosphorylation status of the kinase domain of ERK5 in human T CD4+ cells reduced CD3ζ ubiquitination and degradation, limiting TCR/CD3 down-regulation in anti-CD3-stimulated cells. Moreover, TCR/CD3 recovery at the cell surface, after anti-CD3ε treatment, is impaired by ERK5 knockdown or pharmacological inhibition of autophosphorylation in the ERK5 C-terminal region. ERK5 loss in thymocytes augmented cellular CD3ζ, and increased cell surface levels of TCR/CD3 on CD4+CD8α thymocytes. This correlated with enhanced generation of CD4+CD8α CD25+ thymocytes. Our findings define ERK5 as a novel kinase that modulates the levels of TCR/CD3 at the cell surface by promoting CD3ζ degradation and TCR/CD3 recovery after TCR stimulation. J. Leukoc. Biol. 99: 143-152; 2016.

Introduction

T cell activation depends on the TCR/CD3 complex recognizing specific peptides on the MHC. The TCR/CD3 complex is a multimeric receptor composed of 4 noncovalently attached dimers: the antigen-binding TCR-αβ, as well as CD3ζ, CD3ε, and CD3δζ chains. Regulation of TCR/CD3 complex levels on the cell surface is a dynamic phenomenon that is coordinated through multiple pathways to ensure correct signal transmission. The cell-surface levels of the TCR/CD3 complex present a balance among internalization, recycling, and degradation of existing complexes and the expression of new ones that must be fully assembled before reaching the cell surface [1]. Expression of the TCR/CD3 complex in mature T cells is stable and shows a cycling behavior, with ~30% of the complexes found within endosomal compartments [2]. However, stimulation by TCR/CD3 triggers its rapid down-regulation by enhancing internalization and degradation and reducing recycling [3], thereby avoiding T cell hyperactivation and autoimmunity [4]. In the thymus, thymocytes at the DP stage express 10-fold less TCR/CD3 on the cell surface than SP cells, which is a hypothetical control mechanism for negative and positive selection [5].

ERK5, also known as MAPK7 or big MAPK1, is a member of the MAPK family. The better studied ERK1/2, p38, and JNK kinases play key roles during thymocyte development and in mature T cells after TCR/CD3 stimulation [6]. ERK5 consists of an N-terminal region with a TEY domain, similarly to ERK1/2, and a large C-terminal region with transcriptional activity after autophosphorylation [7]. ERK5 activation occurs by dual phosphorylation of its TEY domain that is mediated by MEK5 [8]. The MEK5/ERK5 pathway is essential for proper blood vessel and cardiac development; thus, ERK5-deficient mice typically die at d 10 or 11 of gestation [9]. In addition, ERK5 is strongly implicated in tumorigenesis, and targeted use as an anti-cancer therapy has been investigated [10, 11]. During T cell development, TCR/CD3 stimulation by strong or weak agonists activates the MEK5-ERK5 pathway; thus, ERK5-deficient mice typically die at d 10 or 11 of gestation [9]. In addition, ERK5 is strongly implicated in tumorigenesis, and targeted use as an anti-cancer therapy has been investigated [10, 11]. During T cell development, TCR/CD3 stimulation by strong or weak agonists activates the MEK5-ERK5 pathway; thus, ERK5-deficient mice typically die at d 10 or 11 of gestation [9].

In this study, we use genetic and pharmacological approaches in human and mouse T cells to demonstrate that ERK5 promotes CD3ζ degradation and TCR/CD3 recovery after anti-CD3ε stimulation.

Abbreviations: AICD = activation-induced cell death, APC = allophycocyanin, DP = double-positive, EGFP = enhanced GFP, Foxp3 = forkhead box P3, Lamp-1 = lysosomal-associated membrane protein 1, LAPTMs = lysosomal protein transmembrane 5, loxP = locus of crossover of P1, MFI = mean fluorescence intensity, MHC-I = MHC class I, sh = short hairpin, siSh = scrambled sh sequence, SLAP = Src-like adaptor protein, SP = single-positive, TEY domain = threonine-glutamic acid-tyrosine activation domain, Treg = regulatory T cell, tTreg = thymus-derived regulatory T cell

The online version of this paper, found at www.jleukbio.org, includes supplemental information.

1. Correspondence: Faculty of Biology, Universitat de Barcelona, Av. Diagonal 645, 08028, Barcelona, Spain. E-mail: esepel@ub.edu (E.E.); mreina@ub.edu (M.R.)

© Society for Leukocyte Biology 2017

0741-5400/16/0099-143

The online version of this paper, found at www.jleukbio.org, includes supplemental information.

Journal of Leukocyte Biology

Volume 99, January 2016

JLB

143

Journal of Leukocyte Biology

Vol.99, No.1, pp:143-152, October, 2017

Downloaded from www.jleukbio.org to IP 54.70.40.11. Journal of Leukocyte Biology Vol.99, No.1, pp:143-152, October, 2017
stimulation. Consequently, we show that ERK5 contributes to the control of TCR/CD3 complex expression on the cell surface.

**MATERIALS AND METHODS**

**Antibodies and reagents**

The mAb anti-human-CD11a (clone MEM-25), anti-human-CD18 (clone W6/32) and Annexin V-FITC conjugated were from ImmunoTools (Friesoythe, Germany). The mAb anti-human-TCR/β (clone IP26), anti-mouse-CD4-APC (clone RM4-5), anti-mouse-CD8-FITC (clone 53-6.7), anti-mouse-CD6-APC-PE (clone 145-2C11), and anti-mouse-CD25-PE (clone 3C7) were from BioLegend (San Diego, CA, USA). Purified no azide/low endotoxin hamster anti-mouse-CD3ε (clone 145-2C11) was from BD Biosciences (San Jose, CA, USA). The anti-human-CD3ε mAb (IgG2a; clone 33-2A3) was from Immunostep (Salamanca, Spain). The anti-TCR (clone OX19) and anti-CD3 (clone P14D1) were from Santa Cruz Biotechnology (Cypress, CA, USA). The polyclonal anti-ERK5 was from Cell Signaling Technology (Danvers, MA, USA). Rabbit anti-Lamp-I-Cy3 and anti-β-actin (clone AC-40) were from Sigma-Aldrich (St. Louis, MO, USA). Alexa 488-labeled secondary antibodies were all from Life Technologies (Grand Island, NY, USA). The ERK5 inhibitor BIX02188 was from Selleckchem.com (Houston, TX, USA), and XMD8-92 was from Tocris Bioscience (Bristol, United Kingdom). The cyclohexamide was from Sigma-Aldrich.

**Isolation of murine splenocytes and cell cultures**

The spleens were extracted freshly by dissection and disaggregated mechanically to obtain a single-cell suspension. The splenocytes were treated with RBC lysis buffer for 15 min at room temperature before being pelleted by centrifugation and then cultured to 10⁷ cells/ml. Murine splenocytes, primary human T cells, Jurkat, sh cells, and shERK5 cells were cultured in RPMI, supplemented with 10% FCS, 2 mM l-glutamine, and penicillin/streptomycin and maintained at 37°C in 5% CO₂. Murine DP thymocyte purification

Thymuses were extracted freshly by dissection and disaggregated mechanically to obtain a single-cell suspension. DP thymocytes were purified by sorting on a FACS Aria (BD Biosciences), by gating on the CD4⁻ and CD8⁻ population (purities up to 95% were obtained). The cells were lysed and analyzed by Western blotting or real-time PCR.

**Generation of stable cell lines**

Jurkat E6.1 human T cells were obtained from the European Collection of Cell Cultures (Sigma-Aldrich). One million Jurkat T cells were stably transfected by electroporation (Multiporator; Eppendorf, Hamburg, Germany) with a scrambled shRNA expression vector or ERK5-specific shRNA expression vector directed to a conserved Erk5 sequence in exon 2 (ref. TRCN0000001354; Sigma-Aldrich) and cultured in 10 wells of 24-well plates with medium containing 1 μg/ml puromycin. A total of 9 shs and 10 shERK5 cell lines was obtained and used in this study.

**Isolation of human T cells**

All of the studies involving human samples were approved by the Ethics Committee of the Universitat de Barcelona. Primary human T cells of healthy blood donors were obtained from buffy coats at Banc de sang i Teixits (Blood and Tissue Bank, Barcelona, Spain). PBMCs were isolated by a ficoll 1.07 density gradient (Lymphoprep, ref. 111454; Axis-Shield, Dundee, Scotland), and resting T CD4⁺ cells were purified by negative selection by use of affinity chromatography (Cedarlane, Ontario, Canada), as described in the manufacturer’s protocol (typical purity ≥ 90%). To prepare activated human T CD4⁺ cells, resting T CD4⁺ cells were activated with PHA (10 μg/ml), anti-CD28 (hybridoma CRK248 supernatant), and IL-2 (20 U/ml). After 3 d at 37°C, T cells were washed twice and cultured for 1 d in RPMI (ref. BE12702F; Lonza, Basel, Switzerland) and 10% FCS before their use in experiments.

**Real-time quantitative PCR**

Cells were lysed, their total RNA was reverse transcribed (SuperScript III, ref. 11752-050; Life Technologies), and real-time PCR was performed in the StepOne Real-Time PCR system (Applied Biosystems, Life Technologies) by use of GoTaq qPCR Master Mix (ref. A6001; Promega, Madison, WI, USA). The oligonucleotides used for human ERK5 were 5’-GCCATAGGATGTTGTCGGT-3’ (sense) and 5’-GGTGGCTTTCCATCAGGTGC-3’ (antisense). The oligonucleotides used for human Cδ3 were 5’-CAGCCTTCCTTTCTGAGGAAA-5’ (sense) and 5’-TCTCAGGAACAGACCGTGA-3’ (antisense). The oligonucleotides used for mouse CD3δ were 5’-AGCCCTGTACCTGAAGCAGA-3’ (sense) and 5’-CTGTTCGGCTCCATCTCGT-3’ (antisense). For all samples, the expression levels were normalized to 18S RNA with oligonucleotides from TATAA (antisense). The relative quantification value was calculated as described elsewhere [18].

**Western blot**

A total cell extract was prepared from 10⁶ cells dissolved in 100 μl of an SDS loading buffer. The cell extract was incubated at 95°C for 30 min before loading on 8, 10, or 12% SDS polyacrylamide gel and then transferred to a nitrocellulose membrane. Western blots were quantitated by chemiluminescence detection by use of a Kodak X-OMAT film or a Luminescent Image Analyzer LAS-3000 (Fujifilm, Tokyo, Japan). Densitometric analysis of proteins was performed by use of Fiji software. All analysis involved normalizing to actin as a loading control.

**Flow cytometry**

Flow cytometric analyses were performed as described previously [19]. Samples were analyzed on a Gallios flow cytometer (Beckman Coulter, Brea, CA, USA). Apoptosis was determined by incubating the thymocytes in binding buffer (10 mM Hepes pH 7.4, 140 mM NaCl, 2.5 mM CaCl₂) with Annexin V-FITC and propidium iodide.

**Confocal microscopy**

Cells were fixed, permeabilized, and stained as in intracellular flow cytometry with mouse antibodies against CD3ε or CD₅₉ and rabbit antibody against LAMP-1 conjugated with Cy3. Then, cells were washed and incubated with anti-mouse Alexa 488 (Invitrogen). Finally, the cells were washed and resuspended in 7 μl Fluoromount mounting medium, applied to microscope slides, and covered with coverslips. Immunostained samples were viewed under a Leica TCS-SP confocal microscope at Leitz Plan apochromatic 60× (NA, 0.7, oil) objective at room temperature. Pictures were acquired by use of the Leica Application Suite software. Final images were processed by Fiji software.

**CD₅₉ ubiquitination analysis**

For the immunoprecipitation experiments, 50 x 10⁶ PBMCs were treated with DMso or BIX02188 (10 μM). After 1 h at 37°C, the cells were stimulated with anti-CD3ε (clone 33-2A5; 0.5 μg/ml) for 6 h, washed twice, and lysed in 1 ml lysis buffer (10 mM Tris HCl, pH 7.5, 10 mM NaCl, 1% Triton X-100, 2.5 mM DTT, 0.1 mM EDTA, 0.1 mM EGTA, and inhibitors of proteases and phosphatases). The lysates were precleared overnight at 4°C with agarose beads, immunoprecipitated with CD59 antibody, and separated by SDS-PAGE.
before Western blotting. The membrane was probed with ubiquitin antibody or CD3ζ antibody.

**TUNEL assay**

The thymuses were fixed immediately after killing with 10% neutral formalin and embedded in paraffin. Thin tissue sections were cut at 10 μm and deparaffinized before TUNEL staining was performed by use of an In Situ Cell Death Detection Kit (ref. 12157929010; Roche Diagnostics, Indianapolis, IN, USA), according to the manufacturer’s protocol. The thymus sections were visualized with an Olympus BX60 epifluorescence microscope by use of a ×20 objective, and images were taken with an Olympus DP70 camera. The final images were processed by Fiji software.

**Statistics**

Data are expressed as the means ± sd from 3 or more independent experiments. Differences between groups were compared by use of Student t tests for 2 groups; 2-way ANOVA with Bonferroni post hoc correction was used for groups with 2 independent variables. Statistical analysis was carried out by use of GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Significance levels are indicated in the figure legends.

**RESULTS**

**ERK5 knockdown in Jurkat T cells led to higher cell-surface levels of TCR/CD3**

To define the role of ERK5 in T cells, we initially targeted ERK5 in Jurkat leukemic T CD4+ cells by use of shRNA-mediated knockdown directed to a conserved Erk5 sequence in exon 2 (shERK5; Fig. 1A and B). Interestingly, ERK5 reduction led to higher levels of CD3ε (Fig. 1C) and TCR-α/β (Fig. 1D) at the cell surface compared with control cell lines transfected with shS. Up-regulation of CD3ε and TCR-α/β by ERK5 knockdown was specific, as the expression of other abundant cell membrane proteins, such as MHC-I (Supplemental Fig. 1A) or LFA-1 (CD11a/CD18; Supplemental Fig. 1B and C), was not altered. Moreover, CD3ε up-regulation was not a result of augmented total amounts of this protein in shERK5 cell lines (Fig. 1E). Importantly, TCR/CD3 up-regulation in shERK5 cell lines correlates with an enhanced AICD (Supplemental Fig. 1D). These results suggest a possible role for ERK5 in the regulation of TCR/CD3 expression at the cell surface in Jurkat T cells.

**ERK5 knockdown in Jurkat T cells led to higher CD3ζ protein levels and reduced TCR/CD3 recovery at the cell surface after anti-CD3ζ stimulation**

Given that the control of CD3ζ levels is a key regulatory mechanism for TCR/CD3 complex expression at the cell surface [20], we analyzed the total amount of CD3ζ in shERK5 cell lines and observed a significant increase in the expression of CD3ζ compared with shS cell lines (Fig. 2A). In contrast, CD3ζ mRNA levels were similar in shERK5 and shS cell lines (Fig. 2B), suggesting that CD3ζ chain degradation was reduced in shERK5 cell lines. To test this hypothesis, we measured CD3ζ half-life by incubating the cells with cycloheximide, an inhibitor of protein synthesis, for up to 6 h (Fig. 2C). CD3ζ showed a trend toward an increased half-life in shERK5 cells at 3 h ($P = 0.061$). This difference could account for the incremented CD3ζ levels observed in long-term cultured cells. These results show that increased CD3ζ expression led to increased TCR/CD3 at the surface of shERK5 Jurkat T cells and suggest a role for ERK5 in the regulation of CD3ζ protein levels.

Antigen-stimulated T cells are known to down-regulate TCR/CD3 from the cell surface, a process that rapidly desensitizes the cell [4, 21]. To gain insight in the ERK5 function in the regulation of TCR/CD3 at the cell surface, we promoted TCR/CD3 down-regulation in shS and shERK5 cell lines by stimulation with soluble anti-CD3ζ antibody. Analysis of TCR/CD3 down-regulation by quantitation of cell-surface CD3ζ expression at different time points, showed a similar down-regulation pattern for both shERK5 and control shS cells (Fig. 2D).

The down-regulation of TCR/CD3 in stimulated T cells is reversed after removal of the stimulus [1]. To establish whether

![Figure 1. ERK5-knockdown in Jurkat T cells increased cell-surface levels of TCR/CD3.](image-url)
ERK5 controlled the recovery of TCR/CD3 at the cell surface, we treated shERK5 cells with anti-CD3ε over 6 h, washed the cells to remove the antibody, and cultured them in normal medium for 18 h. Unexpectedly, the surface CD3ε levels in shERK5 cells showed a 40% reduction compared with shS cells (Fig. 2E), suggesting that ERK5 may play a positive role in the TCR/CD3 recovery at the cell surface after anti-CD3ε treatment. Taken together, these data support that ERK5 could alter cell-surface expression of TCR/CD3 by acting in 2 different pathways: CD3ε degradation and TCR/CD3 recovery at cell surface after anti-CD3ε treatment.

Pharmacological inhibition of ERK5 impaired
TCR/CD3 down-regulation and reduced its recovery in anti-CD3ε-stimulated T CD4⁺ cells

We next evaluated whether pharmacological inhibition of the MEK5/ERK5 signaling pathway affects TCR/CD3 recovery after anti-CD3ε treatment. The inhibitor BIX02188 suppresses MEK5 catalytic activity and ERK5 phosphorylation in the kinase domain, whereas the inhibitor XMD8-92 blocks ERK5 autophosphorylation at the C-terminal region (Fig. 3A) [7]. At the concentrations used in this study, neither one is known to affect other related MAPKs [10, 11]. Whereas inhibition of the MEK5-dependent phosphorylation status of the ERK5 kinase domain by BIX02188 in TCR⁺ PBMCs from healthy donors during TCR/CD3 recovery did not show differences compared with control cells, ERK5 inhibition with XMD8-92 resulted in an impaired capacity to recover normal levels of TCR/CD3 at the cell surface (Fig. 3B). These data suggest that ERK5 regulates TCR/CD3 recovery at the cell surface after anti-CD3ε treatment through autophosphorylation of its C-terminal region and independently of the MEK5-dependent phosphorylation status of its kinase domain.

We also used these pharmacological inhibitors to analyze the effect of ERK5 during TCR/CD3 down-regulation. Interestingly, when Jurkat cells were CD3 stimulated in the presence of BIX02188 or XMD8-92, the down-regulation of TCR/CD3 was impaired (Fig. 3C and Supplemental Fig. 2A and B), suggesting a role for ERK5 in the control of TCR/CD3 down-regulation. To confirm our results in primary human T CD4⁺ cells, these were stimulated with soluble anti-CD3ε to induce TCR/CD3 down-regulation in the presence or absence of BIX02188 and XMD8-92. Stimulation of resting (Fig. 3D) or activated (Fig. 3E) T CD4⁺ cells with different concentrations of anti-CD3ε led to TCR/CD3 down-regulation, but interestingly, this was significantly impaired in cells treated with BIX02188. This confirmed a role for the MEK5/ERK5 signaling pathway in the regulation of cell-surface levels of TCR/CD3. Treatment with XMD8-92 did not modify TCR/CD3 down-regulation in resting (Fig. 3D) or activated (Fig. 3E) cells, suggesting that autophosphorylation of the C-terminal region of ERK5 was not involved in the regulation of TCR/CD3 down-regulation during anti-CD3ε treatment. The inhibition of the MEK5/ERK5 signaling pathway by BIX02188 did not affect TCR/CD3 down-regulation in the 1st 30 min, but after this time, down-regulation was arrested in BIX02188-treated resting (Fig. 3F) or activated (Fig. 3G) T CD4⁺ cells. Of note, stimulation of Jurkat cells with anti-CD3ε led to TCR/CD3 down-regulation of >50% (Fig. 3C and Supplemental Fig. 2A and B), an extent that we did not observe in primary human T CD4⁺ cells. This suggested a role for the phosphorylation of the C-terminal domain of ERK5 in the control of TCR/CD3 down-regulation during strong signaling.
Figure 3. TCR/CD3 down-regulation by anti-CD3ε treatment is impaired by pharmacological inhibition of ERK5. (A) Mechanism of action of ERK5 pathway inhibitors. P, phosphorylation; MEKK, MEK kinase; KD, kinase domain; NKD, nonkinase domain; N, N terminus; C, C terminus. (B) TCR/CD3 recovery after anti-CD3ε treatment in TCR+ PBMCs, which were stimulated with anti-CD3ε (0.3 μg/ml) for 6 h at 37°C in the presence (left) or absence (right) of DMSO, BIX02188 (10 μM), or XMD8-92 (10 μM). Then, cells were washed twice to remove the antibody before culturing them during 18 h in medium with inhibitors and stained as in Fig. 2D. TCR/CD3 recovery was normalized to the shS cell line, given an arbitrary value of 1.0; n = 3. (C) Jurkat T cells treated with DMSO, BIX02188 (10 μM), or XMD8-92 (10 μM). After 1 h at 37°C, cells were stimulated with anti-CD3ε (clone 33-2A3; 0.3 μg/ml) for 4 h at 37°C. The cells were then incubated with saturating amounts of the same anti-CD3ε, followed by staining with Alexa 488-conjugated F(ab′)2 (continued on next page).
ERK5 controlled CD3ξ ubiquitination and degradation during TCR/CD3 down-regulation

Results from shERK5 cell lines suggested a role for ERK5 in CD3ξ degradation. To prove it, we treated activated T CD4+ cells with soluble anti-CD3ζ over 6 h to induce CD3ξ degradation in the presence or absence of BIX02188. Whereas cellular levels of CD3ξ decreased with CD3ζ stimulation, treatment with BIX02188 blocked CD3ξ degradation (Fig. 4A). Importantly, in unstimulated cells, the inhibitor alone does not affect the CD3ξ steady state (Supplemental Fig. 2C), indicating that the kinase domain of ERK5 promotes CD3ξ degradation after CD3ζ stimulation. Confocal microscopy was then performed to visualize the effect of BIX02188 on CD3ζ and CD3ξ distribution in T CD4+ cells. As expected from flow cytometry and Western blot analysis, CD3ζ stimulation caused internalization of CD3ζ and CD3ξ and reduction of CD3ξ (Fig. 4B), with both phenomena spared by BIX02188 treatment.

After TCR triggering, CD3ξ is known to be targeted by ubiquitination before its degradation [22], so next, we tested whether the pattern of CD3ξ ubiquitination was altered by ERK5 activity. PBMCs were stimulated with soluble anti-CD3ζ to induce CD3ξ degradation, in the presence or absence of BIX02188, before cell lysates were prepared, and CD3ξ was immunoprecipitated. As previously seen for T CD4+ cells (Fig. 4A), treatment of PBMCs with BIX02188 impaired the degradation of CD3ξ produced by CD3ζ stimulation (whole-cell lysate; Fig. 4C and Supplemental Fig. 2D). However, CD3ξ was less ubiquitinated in cells treated with BIX02188 (Fig. 4C and Supplemental Fig. 2D), suggesting that the kinase domain of ERK5 promotes CD3ξ ubiquitination. Taken together, these results indicate that the kinase domain of ERK5 promotes TCR/CD3ζ down-regulation by promoting ubiquitination and posterior degradation of CD3ξ.

Splenic T cells from Erk5−/− mice did not show attenuated TCR/CD3ζ down-regulation

To obtain insight into the physiologic significance of ERK5 in T cell function, we bred ERK5-floxed mice to Vav-Cre mice to generate ERK5-specific deficiency in the hematopoietic system (called ERK5−/−; Supplemental Fig. 3A–C). Neither the T cell cellularity (Supplemental Fig. 3D–E) nor the percentages of T CD4+ and CD8+ cells (Supplemental Fig. 3F and G) in the thymus and spleen were altered by the absence of ERK5, which was consistent with previous reports [14, 16] and confirmed that ERK5 was not needed for T cell development and peripheral T cell maintenance.

Our results suggest a role for ERK5 in the regulation of CD3ξ stability and TCR/CD3ζ traffic; however, steady-state, splenic T cells from ERK5−/− and ERK5+/+ mice had similar amounts of CD3ζ at the cell surface (Fig. 5A). Moreover, stimulation of splenocytes with anti-CD3ζ at different time points revealed that TCR/CD3ζ down-regulation was not diminished in the ERK5−/− mice compared with ERK5+/+ mice (Fig. 5B), suggesting that ERK5 does not control TCR/CD3ζ down-regulation in murine splenocytes.

ERK5−/− mice showed reduced degradation of CD3ζ in DP thymocytes

Immature CD4CD8+ DP thymocytes in the thymus express 10-fold less TCR/CD3ζ at the cell surface than mature CD4+ or CD8+ SP thymocytes because of a constitutive ubiquitination of CD3ζ.
Given that ERK5 promotes CD3ζ ubiquitination on peripheral T CD4+ cells after anti-CD3ε stimulation (Fig. 4C), we surmised that ERK5 could play a role in controlling CD3ζ steady state in DP thymocytes. Therefore, we analyzed the total amount of CD3ζ on the immature DP thymocytes of ERK5−/− mice and detected a 2.5-fold increase compared with ERK5+/+ mice (Fig. 5C). Interestingly, CD3ζ mRNA levels were similar in the DP thymocytes of ERK5−/− and ERK5+/+ mice (Fig. 5D), suggesting that ERK5 promoted CD3ζ degradation. In addition, as CD3ζ degradation regulates TCR/CD3 expression on DP thymocytes.
[22], we analyzed CD3ζ expression at the cell surface by flow cytometry. As DP thymocytes express 10-fold less TCR/CD3 at the cell surface than SP cells [5], we separated DP and SP thymocytes by CD3ζ staining intensity (Fig. 5E, histogram). As expected from the analysis of TCR/CD3 expression in splenic T cells (Fig. 5A and B), SP thymocytes from ERK5+/− and ERK5+/+ mice showed the same levels of cell-surface CD3ζ (Fig. 5E) and the same TCR/CD3 down-regulation profile after anti-CD3ζ treatment (Fig. 5F). However, in DP thymocytes of ERK5+/− mice, CD3ζ expression on the cell membrane was slightly increased (Fig. 5E), consistent with the increased CD3ζ levels in these cells. Thus, ERK5 controlled TCR/CD3 levels at the cell surface of immature DP thymocytes by promoting CD3ζ degradation.

Interestingly, cell-surface CD4 and CD8 levels of DP thymocytes and CD4 levels of CD4+ SP thymocytes were slightly down-regulated in ERK5+/− mice (Fig. 5G). We do not know at this point whether the decrease of CD4 and CD8 in DP thymocytes was an indirect consequence of higher TCR expression or a direct effect of the absence of ERK5. However, changes in the relative abundance of TCR/CD3 receptors or CD4 and CD8 coreceptors could affect the selection process through minimum and maximum signaling thresholds that determine the fate of DP thymocytes, which in turn, could lead to death by neglect and negative selection with weak and strong signals, respectively [5]. ERK5 deficiency in Jurkat T cells promotes AICD after anti-CD3ζ stimulation (Supplemental Fig. 1D), and it has been proposed that the MEK5/ERK5 pathway plays a role in negative selection [12]. However, TUNEL staining to determine if ERK5 influences thymocyte apoptosis showed a similar number of TUNEL+ apoptotic thymocytes in ERK5+/− and ERK5+/+ mice (Fig. 6A and Supplemental Fig. 4A). Moreover, FAC5 quantification by Annexin V and propidium iodide staining showed the same amount of apoptotic thymocytes in ERK5+/− compared with ERK5+/+ mice (Fig. 6B). These results indicate that the higher amount of TCR/CD3 at the cell surface of DP thymocytes from ERK5+/− mice does not promote apoptosis. However, the existence of a potential compensatory phenomenon cannot be excluded at this point.

**ERK5−/− mice showed an increased percentage of CD4+CD8−CD25+ thymocytes and reduced percentage of Treg in the spleen**

Up-regulated TCR/CD3 on the cell surface is known to influence the strength of the TCR/CD3 signal by altering TCR avidity for peptide and MHC [1]. During development, CD4+CD8−CD25+Foxp3+ Treg experience stronger TCR/CD3 signals than conventional T cells, and a population enriched in Treg progenitors (CD4+CD8−CD25+Foxp3+) receives even stronger TCR/CD3 signals [23]; therefore, we hypothesized that up-regulation of TCR/CD3 at the cell surface of DP thymocytes could increase the presence of CD4+CD8−CD25+ thymocytes in ERK5+/− mice. To examine the effect of ERK5 deficiency in the development of this thymocyte subpopulation, we analyzed the percentage of CD4+CD8−CD25+ cells in the thymus by flow cytometry. Compared with ERK5+/− mice, the absence of ERK5 increased the CD4+CD8−CD25+ population in the thymus (Fig. 6C), suggesting that ERK5 limited the generation of CD4+CD8−CD25+ thymocytes by down-regulating TCR/CD3 at the cell surface of DP thymocytes via degradation of CD3ζ. To examine further the effect of ERK5 on Treg development, we bred Vav-Cre/ERK5−/− reporter mice to Foxp3+ reporter mice to generate ERK5−/− mice with fluorescently labeled Treg. ERK5+/− mice present a similar percentage of CD4+CD8−CD25+Foxp3+ Treg compared with ERK5+/− mice (Fig. 6D), suggesting a proper Treg development, despite the enrichment in the population of Treg progenitors. Remarkably, ERK5 deletion results in a reduced percentage of Treg in the spleen (Fig. 6E). In summary, ERK5−/− mice show an augmented presence of Treg progenitors and a reduced percentage of Treg in the spleen, with both phenomena apparently unrelated, considering the normal development of the rTreg population.

**DISCUSSION**

In the present study, we used different models to demonstrate that ERK5 has a dual role with antagonistic effects in the modulation of TCR/CD3 complex levels at the cell surface. On one hand, ERK5 knockdown or inhibition of ERK5 autophosphorylation leads to reduced amounts of the TCR/CD3 complex at the cell surface after anti-CD3ζ stimulation. On the other hand, we show several evidences suggesting that ERK5 promotes CD3ζ degradation during anti-CD3ζ stimulation, leading to diminished TCR/CD3 levels at the cell surface. First, knockdown of ERK5 in Jurkat cells resulted in increased amounts of CD3ζ without affecting CD3ζ, which led to higher cell-surface levels of TCR/CD3 (Figs. 1 and 2). Second, inhibition of MEK5-dependent phosphorylation of ERK5 in Jurkat and human T CD4+ cells impaired TCR/CD3 down-regulation after anti-CD3ζ stimulation (Fig. 3). Although ERK5 inhibitors are a proposed therapeutic approach for different cancers [24, 25], our results suggest that such treatment could produce undesired effects on T cell development. Third, DP thymocytes from ERK5+/− mice showed increased CD3ζ (Fig. 5C), probably as a consequence of altered tonic CD3ζ ubiquitination, which is used by DP thymocytes to regulate the levels of TCR/CD3 at the cell surface [22]. Despite the small up-regulation of TCR/CD3, it could account for a shifted signaling threshold and altered selection process. Intriguingly, neither resting nor anti-CD3ζ-stimulated, splenic T cells from the ERK5−/− mice showed altered levels of TCR/CD3 (Fig. 5B). However, we cannot discount the existence of a compensatory phenomenon or the possibility that different TCR/CD3 ligands or longer incubation times could lead to effects similar to those observed in the LAPTM5−/− mice, which shows impaired TCR down-regulation in splenic T cells by promoting lysosomal degradation of CD3ζ after anti-CD3ζ stimulation [26]. This point merits further study.

It was recently proposed that 2 different pathways were able to degrade CD3ζ [27]. These included a LAPTM5-dependent pathway, which promotes degradation of intracellular CD3ζ before assembly in the Golgi apparatus with the TCR-αβCD3ζγCD3ζζ complex [21], and a SLAP/c-Cbl pathway [28], which promotes degradation of recently internalized CD3ζ from the cell surface [4, 29]. We show that ERK5-deficient DP thymocytes display a similar phenotype to LAPTM5-deficient DP thymocytes [26] but that this is less intense than in the SLAP-
c-Cbl-deficient DP thymocytes. Conversely, ERK5 inhibition in T CD4+ cells showed that ERK5 was involved in the ubiquitination and degradation of recently internalized CD3ζ (Fig. 4), suggesting that ERK5 could be involved in the regulation of both pathways. Additional studies will be needed to elucidate the relationship among ERK5, SLAP/c-Cbl, and LAPTM5 signaling pathways in the control of CD3ζ traffic and degradation.

The development of T_{reg} comprises 2 stages [30, 31]: in the 1st stage, SP CD4+CD25+Foxp3+ thymocytes have up-regulated cell-surface CD25, a subunit of the high-affinity IL-2R; in the 2nd stage (CD4+CD25+Foxp33), Foxp3 is induced. The former is TCR/CD3 dependent, and the latter is TCR/CD3 independent and IL-2 dependent [30, 31]. We propose that the up-regulation of TCR/CD3 on DP thymocytes in ERK5−/− mice could account for the shift toward a CD4+CD25+Foxp3+ phenotype. In addition, SLAP deficiency in mice increases the number of T_{reg} [32], suggesting a role for the pathways that controls CD3ζ degradation.

In conclusion, our study identifies ERK5 as a novel kinase that modulates TCR/CD3 expression in mouse and human T cells through the control of CD3ζ degradation and TCR/CD3 recovery after anti-CD3ε treatment. Further studies will be necessary to elucidate the downstream pathways activated by ERK5 that mediate CD3ζ-chain degradation, as well as the implications of this phenomenon in T cell activation and T_{reg} development and function.
AUTHORSHIP
X.R.-C. conceived of, designed, and performed most of the experiments. M.A.-I. and E.E. designed and performed experiments. C.T. provided Erk5loxP/loxP mice. X.R.-C., M.A.-I., M.R., and E.E. analyzed the data. X.R.-C., M.R., and E.E. wrote the manuscript.

ACKNOWLEDGMENTS
This work was supported by Grant FBG300412 from Fundación Bosch i Gimpera (to M.R.). X.R.-C. and M.A.-I. are supported by a predoctoral fellowship from Fundació Bosch i Gimpera (FBG300412). The authors thank the technical staff of the FACS Facility, the staff of the Animal Facility for maintaining the mice, and members of the M.R. laboratory for comments and suggestions.

DISCLOSURES
The authors declare no competing financial interests.

REFERENCES
Dual role of ERK5 in the regulation of T cell receptor expression at the T cell surface

Xavier Rovira-Clavé, Maria Angulo-Ibáñez, Cathy Tournier, et al.

*J Leukoc Biol* 2016 99: 143-152 originally published online August 24, 2015
Access the most recent version at doi:10.1189/jlb.2A0115-034R

**Supplemental Material**
http://www.jleukbio.org/content/suppl/2015/08/24/jlb.2A0115-034R.DC1

**References**
This article cites 32 articles, 15 of which can be accessed free at:
http://www.jleukbio.org/content/99/1/143.full.html#ref-list-1

**Subscriptions**
Information about subscribing to *Journal of Leukocyte Biology* is online at
http://www.jleukbio.org/site/misc/Librarians_Resource.xhtml

**Permissions**
Submit copyright permission requests at:
http://www.jleukbio.org/site/misc/Librarians_Resource.xhtml

**Email Alerts**
Receive free email alerts when new an article cites this article - sign up at
http://www.jleukbio.org/cgi/alerts

© Society for Leukocyte Biology